FICHIT

Je m'inscris

VALNEVA

0/5 (0 note(s))
Note donnée : aucune
Paris
225
Vaccine development and antibody discovery with revenues from a vaccine for Japanese encephalitis and licensed technology platforms
Valneva’s Japanese encephalitis vaccine is licensed in more than thirty-five countries. It is marketed under the trade names IXIARO® in North America, Europe, Hong Kong, Singapore and Israel and under the trade name JESPECT® in Australia and New Zealand where it is distributed by bioCSL.
Valneva's partner Biological E. Ltd. commercializes the Japanese encephalitis vaccine under the trademark JEEV® in India, Pakistan, Nepal and Bhutan. This product is based on Valneva’s technology and manufactured at Biological E.’s facility in Hyderabad, India.
The Pseudomonas aeruginosa program is in Phase II/III development and is part of the strategic alliance between GSK and Valneva.
Valneva aims at developing a vaccine for the prevention of primary Clostridium difficile infection using an age-and risk-based vaccination approach, in persons of advanced age with upcoming hospitalizations or underlying chronic conditions, and eventually for community-wide prophylaxis on an age-based vaccination strategy.
Valneva has developed a multivalent, protein subunit based vaccine candidate against Lyme borreliosis.This candidate has completed pre-clinical development and is currently in the pre-IND-process including regulatory advice and consultation processes (both of which have been completed). Valneva expects to initiate a phase I clinical study in H2 2016.
BACHELOT-FONTAINE Laetitia
www.valneva.com
VLA:FP

Fiche créée le 10/04/2016 par Guillaume   vue 8 fois.